| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
*The Liver Meeting® is a registered trademark of the American Association for the Study of Liver Diseases
As the world leader in the diagnosis and treatment of gastrointestinal conditions for the last 28 years, we know the importance of laboratory testing in a patient's care. Our disease-specific tests are clinically reinforced, cost-effective, and patient care-driven.
In addition to the latest testing, when you partner with us, you extend your network to include some of the world's leading gastroenterology experts. Our clinicians, laboratorians, and genetic counselors are available for consultation seven days a week to provide interpretive expertise and support.
Mayo Clinic Laboratories offers the only comprehensive liver disease testing menu developed by clinical experts to help health care providers determine the underlying cause and rule out other causes for the disease.
FibroTest-ActiTest can be used as a first-line screen to assess the condition of the liver using two diagnostic scores—one for liver fibrosis and one for liver inflammation—based on component tests for six biomarkers.
In the United States, 80 to 100 million people live with NAFLD. More than 25% of these patients will go on to develop NASH. Using a simple blood sample, this test combines 10 standard biomarkers into five scores to provide a complete assessment of the condition of the liver and the five main causes of liver disease including hepatic steatosis, NASH, alcoholic steatohepatitis, fibrosis, and liver inflammation.
To expedite diagnosis and treatment of chronic viral hepatitis, our clinical experts have developed specific testing algorithms to guide the test-ordering process. This approach takes the guesswork out of ordering, and it focuses on test utilization, saving your institution time and money with better patient outcomes from faster turnaround times and treatment options.
| Diagnosis, Detection, and Confirmation |
| Hepatitis B Hepatitis B Surface Antigen, Serum (Mayo ID: HBAG) Hepatitis B Surface Antibody, Qualitative/Quantitative, Serum (Mayo ID: HBAB) Hepatitis B Core Total Antibodies, Serum (Mayo ID: HBC) Hepatitis C Hepatitis C Antibody with Reflex to HCV RNA by PCR, Serum (Mayo ID: HCVDX) Hepatitis C Antibody Screen with Reflex to HCV RNA by PCR, Serum (Mayo ID: HCSRN) Hepatitis E Hepatitis E Virus IgG Antibody, Serum (Mayo ID: HEVG) Hepatitis E Virus IgM Antibody Screen with Reflex to Confirmation, Serum (Mayo ID: HEVM) |
| Quantification |
| Hepatitis B Virus (HBV) DNA Detection and Quantification by Real-Time PCR, Serum (Mayo ID: HBVQN) Hepatitis C Virus (HCV) RNA Detection and Quantification by Real-Time Reverse Transcription-PCR (RT-PCR), Serum (Mayo ID: HCVQN) |
| Genotyping |
| Hepatitis C Virus Genotype, Serum (Mayo ID: HCVG) |
Identifying underlying genetic disorders plays an important role in the treatment and care of patients with liver disease. Appropriate use of screening tests in routine clinical practice can:
| Alpha-1-Antitrypsin (A1A) Deficiency |
| Alpha-1-Antitrypsin Proteotype S/Z by LC-MS/MS, Serum (Mayo ID: A1ALC) SERIPINA1 Gene, Full Gene Analysis (Mayo ID: SERPZ) |
| Hemochromatosis |
| Hemochromatosis HFE Gene Analysis, Blood (Mayo ID: HFE) |
| Wilson Disease |
| First-Tier Screening Ceruloplasmin, Serum (Mayo ID: CERS) Copper Tissue Copper, Liver Tissue (Mayo ID: CUT) Genetic Testing to Confirm Diagnosis and Identify At-Risk Family Members Wilson Disease, Full Gene Analysis (Mayo ID: WDZ) |
Late-onset LAL-D is likely underdiagnosed and frequently identified after liver pathology reveals findings similar to NAFLD or NASH. Early diagnosis of LAL-D is critical to stopping the progression of the disease, as studies have shown that nearly 50% of pediatric and adult LAL-D patients progress to fibrosis, cirrhosis, or liver transplantation within three years of first clinical manifestation.
Autoimmune liver diseases result from inflammatory immune reactions that damage hepatocytes or cholangiocytes. Due to the variance in autoimmune disease forms (which include autoimmune hepatitis [AIH], primary biliary cirrhosis [PBC], and primary sclerosis cholangitis [PSC]), many patients can be misdiagnosed. Early and accurate diagnosis can lead to better treatment outcomes for patients, namely, the avoidance of liver transplants.
Our panel evaluates smooth muscle antibodies (SMA), antinuclear antibodies (ANA), and antimitochondrial antibodies (AMA) for patients with:
Celiac disease may also be associated with severe forms of liver disease and/or coexist with other autoimmune liver diseases. Isolated hypertransaminasemia, with mild or nonspecific histologic changes in the liver biopsy (also known as "celiac hepatitis") is the most frequent presentation of liver injury in celiac disease. Histologic changes and liver enzymes reverse to their normal states after treatment with a gluten-free diet in most patients.
Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer in the world. While HCC can be treated effectively in its early stages, most patients are not diagnosed until they are symptomatic and at higher grades and stages when the disease is less responsive to therapies. Laboratory testing and imaging can identify at-risk patients needing increased surveillance to help aid in early diagnosis.
14. Data collected for μTAS Wako i30 Analyzer and Test Systems US FDA 510(k) Submission.
To speak with a clinical specialty representative and learn more about how our testing can integrate with your practice, call 800-553-1710.
